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Introduction {#s1}
============

Angiogenesis plays a critical role in various pathologic processes, such as in the pathogenesis of ischemic and neoplastic disorders, including central nervous system (CNS) tumors \[[@b1]\]. For example, in CNS tumors, angiogenesis plays a crucial role in both growth and progression \[[@b2]\]. In addition, the presence or absence of florid microvascular proliferation is an important criterion used in the grading of fibrillary astrocytomas \[[@b3]\] and anti-angiogenesis is one of the therapeutic approaches used in high-grade gliomas \[[@b4]\]. Various CNS tumors, including hemangioblastomas (HBs) and glioblastomas (GBMs), are highly vascularized \[[@b1]\]. In many tumors, hypoxia inducible factor-1α (HIF-1α) is regulated by oxygen concentration and is involved in the activation of many genes, including genes that play a role in survival in anaerobic conditions, as well as angiogenesis \[[@b5]\]. In both HBs and GBMs, the accumulation of HIF-1α leads to increased angiogenesis primarily through the upregulation of vascular endothelial growth factor (VEGF) \[[@b1], [@b6]\]. For example, in GBMs, the accumulation of HIF-1α protein causes the upregulation of VEGF mRNA in hypoxic pseudopalisading cells adjacent to areas of necrosis \[[@b1]\]. In HBs however, the decreased degradation and subsequent accumulation of HIF-1α protein is caused by a loss of function of the von-Hippel Lindau (VHL) tumor suppressor protein \[[@b7]\], which causes the upregulation of VEGF mRNA in stromal cells \[[@b1], [@b6]\].

ETS-related gene (ERG) is a transcription factor whose expression in normal physiologic conditions is found in endothelial cells and cells of hematopoietic linage \[[@b8]\]. ERG plays a role in endothelial cell migration and has been linked to angiogenesis \[[@b9]\]. For example, a recent study demonstrated that RhoJ, a Rho GTPase family member highly restricted to endothelial cells in several tissues, is a downstream target of ERG and plays a role in capillary morphogenesis, an important step of the angiogenic cascade \[[@b10]\]. ERG also interacts with other transcription factors in order to regulate various genes that are expressed within the endothelial cell lineage, including VE-cadherin, angiopoetin-2, and von Willebrand Factor (vWF) \[[@b8]\]. Moreover, ERG inhibition leads to endothelial cell apoptosis, as well as a decrease in the total number of endothelial cells, endothelial cell-cell connections, and vascularization \[[@b11]\].

Much has previously been done to assess ERG expression in endothelial cells within vascular lesions. For instance, one recent study demonstrated strong endothelial immunoreactivity for ERG in both benign and malignant vascular tumors, as well as other vascular lesions, including arteriovenous malformations (AVMs) and papillary endothelial hyperplasia \[[@b12]\]. Furthermore, ERG has previously been shown to be both a sensitive and specific marker for endothelial cells in various vascular malignancies, including angiosarcoma, hemangioma, lymphangioma, Kaposi sarcoma, and hemangioendothelioma \[[@b13]\]. Evidence has also demonstrated the presence of ERG overexpression within various non-vascular neoplasms, including prostate carcinoma, Ewing's sarcoma, and acute myeloid leukemia \[[@b14], [@b15], [@b16], [@b17]\]. However, a review of the literature indicates that very little has been done to assess the expression of ERG in CNS tumors, or to compare its reliability with that of other endothelial markers, such as CD31 and CD34. Using immunohistochemistry, and a specific rabbit monoclonal antibody, we evaluated ERG expression in CNS tumors. In addition, immunostains for CD31, CD34, and α-smooth muscle actin (α-SMA) were performed on all samples. We also implemented a quantitative analysis of ERG expression throughout different tumor types using a novel computational methodology via a custom Matlab 2008b program. Overall, our results suggest that ERG is a novel, reliable, and specific marker for endothelial cells in CNS tumors that can be used to better study the process of neovascularization.

Materials and methods {#s2}
=====================

Tissue samples {#sub-s1}
--------------

This Health Insurance Portability and Accountability Act-compliant study was conducted under a protocol approved by the Institutional Review Board of New York University School of Medicine. We evaluated 57 CNS tumors, which included 16 GBMs, of which 1 case was a recurrent high-grade glioma post-radiation therapy; 4 anaplastic astrocytomas (AAs), 8 HBs, 12 meningiomas, 8 metastatic carcinomas, 2 oligodendrogliomas (OGs), 2 hemangiopericytomas (HPCs), 2 solitary fibrous tumors (SFTs), and 3 schwannomas classified according to the World Health Organization ([Table 1](#Table1){ref-type="table"}); as well as 2 AVMs. The tumors were from 30 female and 27 male patients, with an age range of 19 -- 84 years (mean age 53.4). 39 tumors were supratentorial and 18 were infratentorial. Four samples of normal brain tissue removed in the course of surgical exposure were used as controls. When present, normal brain tissue adjacent to the tumor was also used as an internal control.

Immunohistochemistry {#sub-s2}
--------------------

Serial sections were stained for hematoxylin and eosin (H & E) and immunostained with a rabbit monoclonal antibody for ERG (clone EPR3864; 0.8 mg/mL). In addition, mouse monoclonal antibodies were also used to stain sections for CD34 (clone QBEnd/10; 23 mg/mL), CD31 (clone JC70; 0.65 mg/mL), and α-SMA (clone IA4; 0.02 mg/mL). Heat-induced epitope retrieval was done by boiling the deparaffinized tissue sections in 10 mmol/L citrate buffer (pH 6.0) in a 1,200 W microwave oven at 90% output for 64 minutes for ERG, 36 minutes for both CD34 and CD31, and 8 minutes for α-SMA. The sections were allowed to cool to room temperature for 30 minutes and subsequently incubated with secondary antibodies at room temperature overnight on a NexES automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA). We used an anti-rabbit biotinylated goat secondary antibody for ERG and one that was anti-mouse for CD34, CD31, and α-SMA. All primary and secondary monoclonal antibodies were purchased prediluted from Ventana Medical Systems. For each antibody, horseradish peroxidase-conjugated strepavidin with 3,3'-diaminobenzidine was used as the chromogen. Nuclei were lightly counterstained with hematoxylin, and slides were dehydrated and mounted with permanent medium. For each immunostain, control procedures included isotype-matched rabbit and mouse monoclonal antibodies.

Matlab quantitative analysis of ERG expression {#sub-s3}
----------------------------------------------

In each sample of tumor and normal brain tissue, the section immunostained for ERG was evaluated using light microscopy at 100× magnification. The two foci containing the most ERG stained capillaries and microvessels, or "hot spots" within each section were located and used for analysis \[[@b18]\]. Computational analysis of ERG expression was performed using a routine spectral clustering threshold method with custom Matlab 2008b software \[[@b18]\], which provided a pixel count quantification of the presence of the immunostain in each section. Pixels were defined as positively ERG-stained with a threshold value of greater than 55%. We defined an ERG vascular index (EVI) as the sum of pixels with ERG-positive nuclear staining divided by the total number of pixels, multiplied by 100. This corresponds to the percent of ERG-positive stained pixels in the image. An example of use of the Matlab methodology for EVI quantification is demonstrated ([Figure 1](#Figure1){ref-type="fig"}). EVI was calculated for the two foci and the higher value was utilized for quantitative analysis and comparison of different pathologies. The mean EVI for each tumor type and normal brain tissue was calculated and plotted. Statistical analysis with the nonparametric Mann-Whitney test was used to compare percent staining across tumor types and normal brain tissue.

Results {#s3}
=======

Immunohistochemical evaluation of gliomas {#sub-s4}
-----------------------------------------

In all 15 GBMs, all 4 AAs, and the 2 OGs, we observed strong nuclear immunoreactivity for ERG exclusively in endothelial cells lining vascular lumens ([Figure 2](#Figure2){ref-type="fig"}b, [Figure 3](#Figure3){ref-type="fig"}b, [Figure 4](#Figure4){ref-type="fig"}b). For example, in the glomeruloid microvascular proliferation composed of hyperplastic vascular complexes adjacent to pseudopalisading cells surrounding areas of necrosis, ERG was only detected in endothelial cells ([Figure 3](#Figure3){ref-type="fig"}b). In contrast, α-SMA immunoreactivity was detected within the abluminal cells of hyperplastic vessels in GBMs ([Figure 2](#Figure2){ref-type="fig"}e, [Figure 3](#Figure3){ref-type="fig"}e, [Figure 4](#Figure4){ref-type="fig"}d). In the 1 GBM case where microvascular proliferation was absent, endothelial cells were also highlighted by the ERG immunoreactivity. In the post-irradiated GBM, secondary microvascular changes were present and with endothelial cells that were strongly reactive for the ERG immunostain. In GBMs, AAs, and OGs immunoreactivity for CD31 and α-SMA was variable and sometimes weak or even absent within non-hyperplastic vascular channels (Figure 2d, e, [Figure 3](#Figure3){ref-type="fig"}d, e, [Figure 4](#Figure4){ref-type="fig"}d), while immunoreactivity for CD34 was moderate (Figure 2c, [Figure 3c](#Figure3){ref-type="fig"}, [Figure 4c](#Figure4){ref-type="fig"}). In partially sclerosed vessels α-SMA immunoreactivity was reduced, whereas ERG immunoreactivity was present. In addition, in 1 GBM where ERG only stained endothelial cells ([Figure 4](#Figure4){ref-type="fig"}b), CD34 stained both endothelial and tumor cells ([Figure 4](#Figure4){ref-type="fig"}c). ERG-positive endothelial cells were seen at the invasive edge of all GBMs as well.

Immunohistochemical evaluation of HBs {#sub-s5}
-------------------------------------

The 8 HBs were highly vascular ([Figure 5](#Figure5){ref-type="fig"}a). In every case, large areas of tumor showed an anastomosing network of vessels that separated variably abundant groups of stromal cells ([Figure 5](#Figure5){ref-type="fig"}a). In all 8 HBs, like in GBMs, ERG was only expressed in endothelial cells lining vascular lumens, demonstrating markedly diffuse neovascularization, but was not expressed in stromal cells ([Figure 5](#Figure5){ref-type="fig"}b). Unlike ERG, CD31 showed variable and sometimes weak immunoreactivity within endothelial cells ([Figure 5](#Figure5){ref-type="fig"}d), while CD34 showed moderate immunoreactivity ([Figure 5](#Figure5){ref-type="fig"}c). In contrast to ERG, like in GBMs the α-SMA immunostain highlighted abluminal smooth muscle cells within vessels ([Figure 5](#Figure5){ref-type="fig"}e).

Immunohistochemical evaluation of AVMs, HPCs, meningiomas, metastatic carcinomas, schwannomas, and SFTs {#sub-s6}
-------------------------------------------------------------------------------------------------------

Like in gliomas and HBs, in AVMs, HPCs, meningiomas, metastatic carcinomas (Figure 6a), schwannomas, and SFTs, the nuclei of the endothelial cells lining vascular lumens demonstrated strong immunoreactivity for ERG ([Figure 6](#Figure6){ref-type="fig"}b). Here again, like in GBMs, AAs, and HBs, endothelial cells were only variably immunoreactive for CD31, and immunoreactivity for CD34 was more intense than for CD31 ([Figure 6](#Figure6){ref-type="fig"}c). We observed variable α-SMA immunoreactivity within the walls of the vascular channels.

In the 4 control normal brains, and in cerebral and cerebellar tissue adjacent to 12 GBMs, 3 AAs, and 4 HBs, detectable ERG, CD31, and CD34 immunoreactivity was seen in endothelial cells lining vascular lumens. Here again there was stronger immunoreactivity for ERG as compared to CD31, CD34, and α-SMA. α-SMA immunoreactivity was also observed in the media of arteries and arterioles in the 4 control normal brains, as well as in normal brain distant from 1 GBM and 1 AA. For each tumor case and sample of normal brain tissue used in this study, no staining was observed with isotype-matched rabbit and mouse monoclonal antibody controls in the absence of primary antibody.

Matlab quantitative analysis of ERG expression {#sub-s7}
----------------------------------------------

The results of the quantitative analysis of ERG immunoreactivity are summarized in [Figure 7](#Figure7){ref-type="fig"} and [Table 2](#Table2){ref-type="table"}. We demonstrated significantly more extensive ERG expression in HBs than in other CNS tumors, including GBMs (threshold for statistical significance p \< 0.05). Meningiomas and GBMs had the fourth and fifth greatest mean EVIs respectively. As expected, mean EVI was lowest in normal brain tissue. Schwannomas were demonstrated to have the lowest mean EVI of the tumors sampled within our study, and were not found to have significantly more extensive immunostaining for ERG than normal brain tissue. In contrast, meningiomas, metastatic carcinomas, and AAs were found to have significantly more extensive immunostaining for ERG than normal brain tissue.

Discussion {#s4}
==========

ERG is a novel, reliable, and specific marker for endothelial cells within CNS tumors {#sub-s8}
-------------------------------------------------------------------------------------

Our studies demonstrated that in contrast to ERG, CD31 only variably highlighted endothelial cells within CNS tumors and sometimes demonstrated a notably weaker endothelial immunoreactivity. CD31, or platelet endothelial cell adhesion molecule, is a transmembrane glycoprotein expressed in normal physiologic conditions by endothelial cells, platelets, and blood leukocytes, and whose functions include cellular adhesion, platelet activation, and angiogenesis \[[@b18], [@b20]\]. CD31 is one of the most frequently utilized immunohistochemical markers for endothelial cells, for example, as a marker of angiogenesis in the settings of atherosclerosis and abdominal aortic aneurysm \[[@b21]\], for the quantitative analysis of blood vessels \[[@b22]\], and for determining the degree of neovascularization in a variety of neoplasms, including cervical cancer, ovarian cancer, and Kaposi sarcoma \[[@b22], [@b23], [@b24]\].

However, in spite of the ubiquitous use of CD31 as a marker for endothelial cells, this immunostain suffers from various shortcomings. For instance, CD31-positive immunostaining has been reported as a less sensitive marker of microvascular density than other markers within neoplasms such as cervical cancer \[[@b22]\]. Furthermore, the expression of CD31 in platelets and blood leukocytes that are adherent to vascular walls may lead to their misidentification as endothelial cells, thus reducing the specificity of this particular immunostain. Additionally, in our study we observed that CD31 only variably and weakly highlighted endothelial cells within CNS tumors ([Figure 2](#Figure2){ref-type="fig"}d, [Figure 3](#Figure3){ref-type="fig"}d, [Figure 5](#Figure5){ref-type="fig"}d), calling into question this immunostain's use as a marker of such cells.

CD34 is yet another immunostain with widespread utilization as a marker for endothelial cells. CD34 is a transmembrane glycoprotein expressed in normal physiologic conditions by endothelial cells and hematopoietic stem cells, as well as in dural fibroblastic lesions and non-neoplastic fibrous/leptomeningeal lesions, and whose functions include control of differentiation of stem cells and adhesion \[[@b25]\]. Like CD31, CD34 has been proposed as a sensitive marker for endothelial cells \[[@b22]\], has been used to diagnose vascular tumors \[[@b26]\], and has been used to evaluate the degree of angiogenesis in a variety of neoplasms, including cervical cancer, prostate cancer, and multiple myeloma \[[@b22], [@b27], [@b28]\].

However, like CD31, CD34 is affected by several drawbacks which should allow us to question the prevalence of its use as an endothelial cell marker. For instance, CD34-positive immunostaining has also been reported in non-vascular cells within CNS tumors, including solitary fibrous tumor and ganglioglioma \[[@b29], [@b30], [@b31]\], thus limiting the use of CD34 as a specific marker for endothelial cells. In addition, in 1 case of a GBM in our study, CD34 highlighted not only endothelial cells, but also tumor cells ([Figure 4](#Figure4){ref-type="fig"}c).

In our study we have demonstrated that unlike CD31 and CD34, ERG is exclusively expressed in endothelial cells within CNS tumors, lending support to the notion that ERG is a more specific marker for such cells. Furthermore, ERG dependably and intensely highlighted endothelial cells in CNS tumors ([Figure 2](#Figure2){ref-type="fig"}b, [Figure 3](#Figure3){ref-type="fig"}b, [Figure 4](#Figure4){ref-type="fig"}b, [Figure 5](#Figure5){ref-type="fig"}b, [Figure 6](#Figure6){ref-type="fig"}b), providing solid evidence that ERG is a more robust endothelial marker than CD31 and CD34 are. In line with these observations and given the various limitations of the CD31 and CD34 immunostains, we recommend that ERG should be used in the future as the primary endothelial immunostain for CNS tumors.

Quantitative expression of ERG in endothelial cells in CNS tumors {#sub-s9}
-----------------------------------------------------------------

Our results revealed significantly higher ERG expression in HBs than in other CNS tumors, including GBMs, which had the fifth greatest mean EVI. These results are consistent with the diffuse, increased vascular density seen in HBs \[[@b1]\], which contrasts with the multifocal and patchy microvascular proliferation in GBMs, for example, adjacent to areas of necrosis \[[@b1]\]. Therefore, although HBs and GBMs are both highly vascularized, the differences in their mean EVI values may be explained by variations in the overall respective homogenous and heterogeneous distribution and landscape of neovascularization within such tumors. The findings that GBMs had a higher mean EVI than AAs and that both GBMs and AAs had a higher mean EVI than normal brain tissue are consistent with the microvascular proliferation seen within high grade gliomas and compatible with the grade assigned to these neoplasms, for the presence or absence of florid microvascular proliferation is an important criterion used in the grading of gliomas \[[@b3]\]. Similarly, meningiomas and metastatic carcinomas of the brain, in contrast to schwannomas, were found to have a significantly higher mean EVI than normal brain tissue. Our results regarding meningiomas and metastatic carcinomas are in line with the important role that angiogenesis plays in such neoplasms \[[@b32], [@b33]\], providing further evidence that mean EVI correlates with endothelial cell number within CNS tumors. As benign nerve sheath tumors, schwannomas are less likely to have marked angiogenesis than malignant peripheral nerve sheath tumors, also compatible with our results \[[@b34]\].

Use of ERG in understanding the process of neovascularization in gliomas {#sub-s10}
------------------------------------------------------------------------

In our study we observed that ERG was only expressed in the nuclei of endothelial cells lining vascular lumens in normal brain tissue and within CNS tumors, for example, in the glomeruloid microvascular proliferation seen in GBMs. In contrast, α-SMA immunoreactivity was identified in abluminal cells within the hyperplastic vascular complexes of GBMs \[[@b35]\]. Clearly, the accurate delineation of the cellular components taking part in the microvascular proliferation seen in GBMs is important in order to better understand angiogenesis in CNS tumors. One unresolved and still debated issue related to the cellular components contributing to hyperplastic vessels within GBMs continues to exist. Some have shown that only endothelial cells without the involvement of smooth muscle cells are involved in the microvascular proliferation seen in GBMs \[[@b35]\]. In contrast, other studies have provided experimental data indicating that both endothelial and smooth muscle cells are involved in the microvascular proliferation leading to vascular hyperplasia within glial neoplasms \[[@b36]\]. Our results, which demonstrate the presence of both ERG and α-SMA immunostained cells within vascular lumens, provide novel support for the latter hypothesis of a mixed dual cellular component involved in the glomeruloid microvascular proliferation seen in GBMs, consisting of both endothelial and smooth muscle cells.

Conclusion {#s5}
==========

In conclusion, we have shown that ERG is a novel and more reliable marker for endothelial cells within CNS tumors than CD31 and CD34 are, adding another tool to the arsenal for the evaluation of CNS tumors. Furthermore, we have demonstrated that ERG expression is significantly higher in HBs than in other types of CNS tumors, including GBMs. Our results help to elucidate the cellular component of the microvascular proliferation of GBMs, furthering our understanding of the development of angiogenesis in CNS tumors. Future studies involving the ERG immunostain may be undertaken in order to better define the biological mechanisms that underlie the process of neovascularization in CNS tumors.
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###### CNS lesions used for ERG immunohistochemistry.

  Age   Sex   Location                        Pathology
  ----- ----- ------------------------------- --------------------------------
  23    F     Left cerebellum                 Anaplastic astrocytoma
  33    F     Left temporal lobe              Anaplastic astrocytoma
  62    M     Left temporal lobe              Anaplastic astrocytoma
  62    M     Left frontal lobe               Anaplastic astrocytoma
  41    M     Left frontal lobe               Arteriovenous malformation
  69    F     Posterior fossa                 Arteriovenous malformation
  24    F     Right frontal lobe              Glioblastoma
  39    M     Right temporal lobe             Glioblastoma
  41    F     Right parietal lobe             Glioblastoma
  47    M     Left parietal lobe              Glioblastoma
  49    M     Right temporal lobe             Glioblastoma
  56    M     Right frontal lobe              Glioblastoma
  60    M     Left occipital lobe             Glioblastoma (post-irradiated)
  60    M     Left occipital lobe             Glioblastoma
  60    M     Right occipital lobe            Glioblastoma
  61    F     Left parietal lobe              Glioblastoma
  61    F     Left temporal lobe              Glioblastoma
  64    M     Right temporal lobe             Glioblastoma
  67    M     Left frontal lobe               Glioblastoma
  67    F     Left frontal lobe               Glioblastoma
  68    F     Right temporal lobe             Glioblastoma
  71    M     Right frontal lobe              Glioblastoma
  19    M     Midline cerebellum              Hemangioblastoma
  29    F     Left cerebellum                 Hemangioblastoma
  33    M     Midline cerebellum              Hemangioblastoma
  39    F     Midline cerebellum              Hemangioblastoma
  46    F     Left cerebellum                 Hemangioblastoma
  50    F     Left cerebellum                 Hemangioblastoma
  50    F     Right cerebellum                Hemangioblastoma
  63    M     Right cerebellum                hemangioblastoma
  30    F     Right cerebello-pontine angle   Hemangiopericytoma
  38    F     Clivus                          Hemangiopericytoma
  40    F     Left sphenoid wing              Meningioma
  43    F     Left frontal lobe               Meningioma
  46    M     Right temporo-parietal region   Meningioma
  48    F     Right temporal lobe             Meningioma
  49    M     Left suboccpital region         Meningioma
  55    M     Left frontal lobe               Meningioma
  65    F     Right subfrontal region         Meningioma
  66    M     Falcine region                  Meningioma
  69    F     Right sphenoid wing             Meningioma
  71    M     Left fronto-parietal region     Meningioma
  72    F     Tuberculum sella                Meningioma
  73    F     Right retrosigmoid region       Meningioma
  54    F     Right cerebellum                Metastatic carcinoma
  57    F     Right cerebellum                Metastatic carcinoma
  57    F     Left cerebellum                 Metastatic carcinoma
  57    M     Right parietal lobe             Metastatic carcinoma
  61    F     Left cerebellum                 Metastatic carcinoma
  63    M     Right frontal lobe              Metastatic carcinoma
  65    M     Right frontal lobe              Metastatic carcinoma
  66    M     Left cerebellum                 Metastatic carcinoma
  30    M     Right frontal lobe              Oligodendroglioma
  56    M     Left frontal lobe               Oligodendroglioma
  48    M     Left cerebello-pontine angle    Schwannoma
  50    F     Right cerebello-pontine angle   Schwannoma
  56    F     Right cerebello-pontine angle   Schwannoma
  71    F     Left suboccpital region         Solitary fibrous tumor
  84    F     Right suboccipital region       Solitary fibrous tumor
  20    M     Right frontal lobe              Normal brain tissue
  63    M     Right frontal lobe              Normal brain tissue
  63    M     Right frontal lobe              Normal brain tissue
  68    F     Left parietal lobe              Normal brain tissue

![Matlab quantitative determination of EVI. a: Original image of a GBM stained with ERG (100× magnification). b: Demonstration of calculation of degree of ERG staining (EVI = 5.028).](clinneuropathol-34-117-01){#Figure1}

![GBM. a: H & E demonstrates pseudopalisading cells surrounding areas of central necrosis, with associated areas of microvascular proliferation. b: ERG exclusively highlights the nuclei of endothelial cells. c: CD34 highlights endothelial cells. d: CD31 weakly highlights endothelial cells. e: α-SMA highlights smooth muscle cells within the walls of vascular channels. The magnification for a: 100×. The magnification for b -- e: 50×.](clinneuropathol-34-117-02){#Figure2}

![GBM, glomeruloid type. a: H & E demonstrates glomeruloid microvascular proliferation. b: ERG exclusively highlights the nuclei of endothelial cells. c: CD34 highlights endothelial cells. d: CD31 weakly highlights endothelial cells. e: α-SMA highlights smooth muscle cells within the walls of vascular channels. The magnification for a: 100×. The magnification for b -- e: 50×.](clinneuropathol-34-117-03){#Figure3}

![GBM, epithelioid type. a: H & E demonstrates a vascular lumen. b: ERG exclusively highlights the nuclei of endothelial cells. c: CD34 highlights not only endothelial cells, but also tumor cells. d: α-SMA highlights smooth muscle cells within the wall of a vascular channel (a -- d: 200× magnification).](clinneuropathol-34-117-04){#Figure4}

![HB. a: H & E demonstrates markedly diffuse microvascular proliferation. b: ERG exclusively highlights the nuclei of endothelial cells. c: CD34 highlights endothelial cells. d: CD31 weakly highlights endothelial cells. e: α-SMA highlights abluminal smooth muscle cells within hyperplastic vascular complexes. The magnification for a: 100×. The magnification for b -- e: 50×.](clinneuropathol-34-117-05){#Figure5}

![Metastatic carcinoma. a: H & E demonstrates a vascular lumen. b: ERG exclusively highlights the nuclei of endothelial cells. c: CD34 highlights endothelial cells (a -- c 200× magnification).](clinneuropathol-34-117-06){#Figure6}

![EVI of different CNS lesions, plotted with SD.](clinneuropathol-34-117-07){#Figure7}

Table 2.Quantitative and statistical analysis of EVI.PathologyEVISDNHemangioblastoma4.8071.5288Solitary fibrous tumor2.2281.1762Hemangiopericytoma1.9981.4052Meningioma1.8420.95112Glioblastoma1.3740.78816Oligodendroglioma1.350.7972Metastatic carcinoma1.170.8178Anaplastic astrocytoma0.9550.3784Arteriovenous malformation0.7840.5882Schwannoma0.6780.3873Normal brain tissue0.1990.1144Paired tumors with p-valuesHemangioblastomaSolitary fibrous tumorHemangiopericytomaMeningiomaGlioblastomaOligodendrogliomaMetastatic carcinomaAnaplastic astrocytomaArteriovenous malformationSchwannomaSolitary fibrous tumor0.0889Hemangiopericytoma0.04440.667Meningioma0.00010.550.923Glioblastoma\< 0.0050.2090.2610.1Oligodendroglioma0.04440.6670.1330.550.941Metastatic carcinoma0.00020.2670.40.1350.490.711Anaplastic astrocytoma0.0040.1330.5330.1330.4940.5330.808Arteriovenous malformation0.04440.3330.6670.19780.4710.6670.5330.533Schwannoma0.01210.20.40.030.2110.40.4970.40.8Normal brain tissue0.0040.1330.1330.0010.00040.1330.01620.02860.1330.114
